NCT07661784

Brief Summary

This study aims to evaluate salivary biomarkers associated with bone remodeling during the transition from periodontal health to disease. Periodontal diseases are characterized by chronic inflammation that can lead to connective tissue destruction and alveolar bone loss. Although diagnosis is primarily based on clinical and radiographic findings, these methods may not fully reflect disease activity or progression. In this observational study, individuals with periodontal health, gingivitis, and periodontitis will be included. Salivary levels of IL-17, IL-23, IL-6, TGF-β, RANKL, and OPG will be measured using ELISA. The relationship between these biomarkers and periodontal disease stage and grade will be analyzed. The results are expected to improve understanding of the biological mechanisms underlying periodontal disease progression and to assess the potential role of salivary biomarkers in early diagnosis and personalized treatment approaches.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for all trials

Timeline
1mo left

Started Jul 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Jul 2025Aug 2026

Study Start

First participant enrolled

July 10, 2025

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 20, 2026

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 22, 2026

Completed
18 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 10, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2026

Expected
Last Updated

June 22, 2026

Status Verified

June 1, 2026

Enrollment Period

1 year

First QC Date

April 20, 2026

Last Update Submit

June 16, 2026

Conditions

Keywords

Periodontal DiseaseGingivitisPeriodontitisSalivary BiomarkersBone RemodelingInterleukin-17 (IL-17)Interleukin-23 (IL-23)Interleukin-6 (IL-6)Transforming Growth Factor Beta (TGF-β)RANKLOsteoprotegerin (OPG)ELISANon-invasive Diagnosis

Outcome Measures

Primary Outcomes (1)

  • Salivary concentrations of IL-17, IL-23, IL-6, TGF-β, RANKL and OPG

    Salivary concentrations of IL-17, IL-23, IL-6, TGF-β, RANKL and OPG measured using enzyme-linked immunosorbent assay (ELISA). Biomarker concentrations will be reported in pg/mL and compared among periodontal health, gingivitis and periodontitis groups.

    At baseline

Study Arms (3)

Periodontally Healthy

Individuals with clinically healthy periodontal tissues, no signs of gingival inflammation, and no clinical attachment loss. Unstimulated saliva samples will be collected for biomarker analysis.

Other: Saliva Sampling

Gingivitis

Individuals diagnosed with gingivitis characterized by gingival inflammation without clinical attachment loss. Unstimulated saliva samples will be collected for biomarker analysis.

Other: Saliva Sampling

Periodontitis

Individuals diagnosed with periodontitis presenting clinical attachment loss and radiographic evidence of alveolar bone loss. Unstimulated saliva samples will be collected for biomarker analysis.

Other: Saliva Sampling

Interventions

Collection of unstimulated saliva samples from participants for the analysis of inflammatory and bone remodeling-related biomarkers using ELISA methods.

GingivitisPeriodontally HealthyPeriodontitis

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population consists of systemically healthy adult individuals aged 18-65 years who attend the Department of Periodontology at Suleyman Demirel University for routine dental examination and periodontal evaluation. Participants will be classified into periodontally healthy, gingivitis, and periodontitis groups based on clinical periodontal findings.

You may qualify if:

  • Adults aged 18-65 years Systemically healthy individuals Individuals classified as periodontally healthy, gingivitis, or periodontitis according to clinical periodontal examination Ability and willingness to provide informed consent

You may not qualify if:

  • Presence of systemic diseases affecting periodontal status (e.g., diabetes mellitus, immunological disorders) Use of antibiotics or anti-inflammatory drugs within the last 3 months History of periodontal treatment within the last 6 months Pregnancy or lactation Smoking (optional ) Any condition that may affect salivary biomarker levels

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Suleyman Demirel University

Isparta, 32000, Turkey (Türkiye)

RECRUITING

Related Publications (4)

  • Buduneli N, Kinane DF. Host-derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis. J Clin Periodontol. 2011 Mar;38 Suppl 11:85-105. doi: 10.1111/j.1600-051X.2010.01670.x.

    PMID: 21323706BACKGROUND
  • Graves DT, Fine D, Teng YT, Van Dyke TE, Hajishengallis G. The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J Clin Periodontol. 2008 Feb;35(2):89-105. doi: 10.1111/j.1600-051X.2007.01172.x.

    PMID: 18199146BACKGROUND
  • Kinney JS, Morelli T, Braun T, Ramseier CA, Herr AE, Sugai JV, Shelburne CE, Rayburn LA, Singh AK, Giannobile WV. Saliva/pathogen biomarker signatures and periodontal disease progression. J Dent Res. 2011 Jun;90(6):752-8. doi: 10.1177/0022034511399908. Epub 2011 Mar 15.

    PMID: 21406610BACKGROUND
  • Dommisch H, Hoedke D, Lu EM, Schafer A, Richter G, Kang J, Nibali L. Genetic Biomarkers for Periodontal Diseases: A Systematic Review. J Clin Periodontol. 2025 Aug;52 Suppl 29(Suppl 29):182-210. doi: 10.1111/jcpe.14149. Epub 2025 Apr 8.

    PMID: 40197750BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Unstimulated whole saliva samples will be collected from participants using standard collection protocols. The samples will be processed and stored under appropriate laboratory conditions for the analysis of inflammatory and bone remodeling-related biomarkers, including IL-17, IL-23, IL-6, TGF-β, RANKL, and OPG. No DNA or genetic analyses will be performed.

MeSH Terms

Conditions

Periodontal DiseasesGingivitisPeriodontitisCamurati-Engelmann Syndrome

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic DiseasesInfectionsGingival DiseasesOsteochondrodysplasiasBone Diseases, DevelopmentalBone DiseasesMusculoskeletal DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Erensu Uzar Gürtan, DDS, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Periodontology

Study Record Dates

First Submitted

April 20, 2026

First Posted

June 22, 2026

Study Start

July 10, 2025

Primary Completion

July 10, 2026

Study Completion (Estimated)

August 30, 2026

Last Updated

June 22, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be publicly shared due to privacy and ethical considerations. The study involves sensitive clinical and biological data, and sharing such information may compromise participant confidentiality.

Locations